Galanin in Alzheimer's disease: Neuroinhibitory or neuroprotective?

37Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Galanin (GAL) and GAL receptors (GALRs) are overexpressed in degenerating brain regions associated with cognitive decline in Alzheimer's disease (AD). The functional consequences of GAL plasticity in AD are unclear. GAL inhibits cholinergic transmission in the hippocampus and impairs spatial memory in rodent models, suggesting GAL overexpression exacerbates cognitive impairment in AD. By contrast, gene expression profiling of individual cholinergic basal forebrain (CBF) neurons aspirated from AD tissue revealed that GAL hyperinnervation positively regulatesmRNAs that promote CBF neuronal function and survival. GAL also exerts neuroprotective effects in rodent models of neurotoxicity. These data support the growing concept that GAL overexpression preserves CBF neuron function which in turn may slow the onset of AD symptoms. Further elucidation of GAL activity in selectively vulnerable brain regions will help gauge the therapeutic potential of GALR ligands for the treatment of AD. (Part of a Multi-author Review). © 2008 Birkhaueser.

Cite

CITATION STYLE

APA

Counts, S. E., Perez, S. E., & Mufson, E. J. (2008, June). Galanin in Alzheimer’s disease: Neuroinhibitory or neuroprotective? Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-008-8159-2

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free